Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells.

Neuroblastoma is the most common cancer in infants and the fourth most common cancer in children. Aggressive cell growth and chemoresistance are notorious obstacles in neuroblastoma therapy. Exposure to the anticancer drug ellipticine inhibits efficiently growth of neuroblastoma cells and induces apoptosis in these cells. However, ellipticine induced resistance in these cells. The upregulation of a vacuolar (V)-ATPase gene is one of the factors associated with resistance development. In accordance with this finding, we found that levels of V-ATPase protein expression are higher in the ellipticine-resistant UKF-NB-4ELLI line than in the parental ellipticine-sensitive UKF-NB-4 cell line. Treatment of ellipticine-sensitive UKF-NB-4 and ellipticine-resistant UKF-NB-4ELLI cells with ellipticine-induced cytoplasmic vacuolization and ellipticine is concentrated in these vacuoles. Confocal microscopy and staining of the cells with a lysosomal marker suggested these vacuoles as lysosomes. Transmission electron microscopy and no effect of an autophagy inhibitor wortmannin ruled out autophagy. Pretreatment with a V-ATPase inhibitor bafilomycin A and/or the lysosomotropic drug chloroquine prior to ellipticine enhanced the ellipticine‑mediated apoptosis and decreased ellipticine-resistance in UKF-NB-4ELLI cells. Moreover, pretreatment with these inhibitors increased formation of ellipticine-derived DNA adducts, one of the most important DNA-damaging mechanisms responsible for ellipticine cytotoxicity. In conclusion, resistance to ellipticine in the tested neuroblastoma cells is associated with V-ATPase-mediated vacuolar trapping of this drug, which may be decreased by bafilomycin A and/or chloroquine.

[1]  V. Adam,et al.  Expression Levels of Enzymes Metabolizing an Anticancer Drug Ellipticine Determined by Electromigration Assays Influence its Cytotoxicity to Cancer Cells - A Comparative Study , 2014, International Journal of Electrochemical Science.

[2]  J. Rubinstein,et al.  Eukaryotic V-ATPase: novel structural findings and functional insights. , 2014, Biochimica et biophysica acta.

[3]  E. Frei,et al.  Ellipticines as DNA-targeted chemotherapeutics. , 2014, Current medicinal chemistry.

[4]  D. Richardson,et al.  P-glycoprotein Mediates Drug Resistance via a Novel Mechanism Involving Lysosomal Sequestration* , 2013, The Journal of Biological Chemistry.

[5]  Xiaofei Li,et al.  ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells , 2012, Diagnostic Pathology.

[6]  Wayne F. Patton,et al.  Interactions between autophagic and endo-lysosomal markers in endothelial cells , 2012, Histochemistry and Cell Biology.

[7]  V. Adam,et al.  The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. , 2012, Current medicinal chemistry.

[8]  Sheng Lu,et al.  Self-assembling peptide-based nanoparticles enhance anticancer effect of ellipticine in vitro and in vivo , 2012, International journal of nanomedicine.

[9]  M. Prata,et al.  Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. , 2012, Molecular genetics and metabolism.

[10]  Z. Zemanová,et al.  Mechanisms of ellipticine‐mediated resistance in UKF‐NB‐4 neuroblastoma cells , 2012, Cancer science.

[11]  K. Takeda,et al.  α5β1 integrin antagonists reduce chemotherapy‐induced premature senescence and facilitate apoptosis in human glioblastoma cells , 2010, International journal of cancer.

[12]  G. Citro,et al.  Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy , 2010, Journal of experimental & clinical cancer research : CR.

[13]  V. Solomon,et al.  Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. , 2009, European journal of pharmacology.

[14]  R. Rajewski,et al.  Mechanisms of amine accumulation in, and egress from, lysosomes. , 2009, Bioanalysis.

[15]  R. Breitling,et al.  Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells , 2009, Molecular Cancer.

[16]  R. Kizek,et al.  The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. , 2009, Biochemical pharmacology.

[17]  H. Wieczorek,et al.  Inhibitors of V-ATPases: old and new players , 2009, Journal of Experimental Biology.

[18]  N. Cheong,et al.  Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration , 2008, Leukemia.

[19]  V. Arlt,et al.  Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. , 2008, Toxicology and applied pharmacology.

[20]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. , 2007, Cancer letters.

[21]  E. Frei,et al.  Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. , 2007, Toxicology.

[22]  E. Frei,et al.  Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12‐hydroxyellipticine and 13‐hydroxyellipticine , 2007, International journal of cancer.

[23]  Eva Frei,et al.  Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine. , 2006, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[24]  R. Schmidt,et al.  Bafilomycin A1 Inhibits Chloroquine-Induced Death of Cerebellar Granule Neurons , 2006, Molecular Pharmacology.

[25]  A. von Deimling,et al.  Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. , 2005, International journal of oncology.

[26]  J. Hudeček,et al.  The Anticancer Drug Ellipticine Forms Covalent DNA Adducts, Mediated by Human Cytochromes P450, through Metabolism to 13-Hydroxyellipticine and Ellipticine N2-Oxide , 2004, Cancer Research.

[27]  V. Rodriguez,et al.  Wilms' tumor and neuroblastoma , 2004, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[28]  N. Garbett,et al.  Extending nature's leads: the anticancer agent ellipticine. , 2004, Current medicinal chemistry. Anti-cancer agents.

[29]  E. Frei,et al.  DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling , 2003, International journal of cancer.

[30]  Brenda Baggett,et al.  Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. , 2003, Biochemical pharmacology.

[31]  Barbara Hero,et al.  Neuroblastoma: biology and molecular and chromosomal pathology. , 2003, The Lancet. Oncology.

[32]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[33]  V. Arlt,et al.  Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. , 2002, Biochemical pharmacology.

[34]  E. Frei,et al.  The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. , 2001, Biochemical pharmacology.

[35]  Toshitaka Nakamura,et al.  Elevated expression of vacuolar proton pump genes and cellular ph in cisplatin resistance , 2001, International journal of cancer.

[36]  R. Gillies,et al.  pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. , 1999, Biochemical pharmacology.

[37]  H. Geuze,et al.  Intracellular trafficking of lysosomal membrane proteins , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  M. Zvelebil,et al.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction , 1996, Molecular and cellular biology.

[39]  S. Simon,et al.  Intracellular pH and the control of multidrug resistance. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Arcaro,et al.  Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. , 1993, The Biochemical journal.

[41]  K. Altendorf,et al.  Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[42]  V. Adam,et al.  Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. , 2012, Pharmacology & therapeutics.

[43]  R. Kizek,et al.  Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. , 2011, Neuro endocrinology letters.

[44]  E. Frei,et al.  Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency. , 2011, Biochimica et biophysica acta.

[45]  E. Frei,et al.  Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. , 2009, Neuro endocrinology letters.

[46]  T. Ueno,et al.  LC3 and Autophagy. , 2008, Methods in molecular biology.

[47]  A. Meijer,et al.  The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. , 1997, European journal of biochemistry.